| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Clinical Investigations |
1 Department of Gynecology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
2 Department of Nuclear Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany
3 Division of Nuclear Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Chemotherapy is currently the treatment of choice for patients with high-risk metastatic breast cancer. Clinical response is determined after several cycles of chemotherapy by changes in tumor size as assessed by conventional imaging procedures including CT, MRI, plain film radiography, or ultrasound. The aim of this study was to evaluate the use of sequential 18F-FDG PET to predict response after the first and second cycles of standardized chemotherapy for metastatic breast cancer. Methods: Eleven patients with 26 metastatic lesions underwent 31 18F-FDG PET examinations (240–400 MBq of 18F-FDG; 10-min 2-dimensional emission and transmission scans). Clinical response, as assessed by conventional imaging after completion of chemotherapy, served as the reference. 18F-FDG PET images after the first and second cycles of chemotherapy were analyzed semiquantitatively for each metastatic lesion using standardized uptake values (SUVs) normalized to patients’ blood glucose levels. In addition, whole-body 18F-FDG PET images were viewed for overall changes in the 18F-FDG uptake pattern of metastatic lesions within individual patients and compared with conventional imaging results after the third and sixth cycles of chemotherapy. Results: After completion of chemotherapy, 17 metastatic lesions responded, as assessed by conventional imaging procedures. In those lesions, SUV decreased to 72% ± 21% after the first cycle and 54% ± 16% after the second cycle, when compared with the baseline PET scan. In contrast, 18F-FDG uptake in lesions not responding to chemotherapy (n = 9) declined only to 94% ± 19% after the first cycle and 79% ± 9% after the second cycle. The differences between responding and nonresponding lesions were statistically significant after the first (P = 0.02) and second (P = 0.003) cycles. Visual analysis of 18F-FDG PET images correctly predicted the response in all patients as early as after the first cycle of chemotherapy. As assessed by 18F-FDG PET, the overall survival in nonresponders (n = 5) was 8.8 mo, compared with 19.2 mo in responders (n = 6). Conclusion: In patients with metastatic breast cancer, sequential 18F-FDG PET allowed prediction of response to treatment after the first cycle of chemotherapy. The use of 18F-FDG PET as a surrogate endpoint for monitoring therapy response offers improved patient care by individualizing treatment and avoiding ineffective chemotherapy.
Key Words: 18F-FDG • PET • metastases • breast cancer • prediction of response to therapy
This article has been cited by other articles:
|
|
 |
|
  K. McLarty, A. Fasih, D. A. Scollard, S. J. Done, D. C. Vines, D. E. Green, D. L. Costantini, and R. M. Reilly 18F-FDG Small-Animal PET/CT Differentiates Trastuzumab-Responsive from Unresponsive Human Breast Cancer Xenografts in Athymic Mice J. Nucl. Med., November 1, 2009; 50(11): 1848 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. De Giorgi, V. Valero, E. Rohren, S. Dawood, N. T. Ueno, M. C. Miller, G. V. Doyle, S. Jackson, E. Andreopoulou, B. C. Handy, et al. Circulating Tumor Cells and [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer J. Clin. Oncol., July 10, 2009; 27(20): 3303 - 3311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Lee, E. L. Rosen, and D. A. Mankoff The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions J. Nucl. Med., May 1, 2009; 50(5): 738 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Avril, S. Sassen, and R. Roylance Response to Therapy in Breast Cancer J. Nucl. Med., May 1, 2009; 50(Suppl_1): 55S - 63S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Laing, M. A. Walter, D. O. Campbell, H. R. Herschman, N. Satyamurthy, M. E. Phelps, J. Czernin, O. N. Witte, and C. G. Radu Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography PNAS, February 24, 2009; 106(8): 2847 - 2852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schwarz-Dose, M. Untch, R. Tiling, S. Sassen, S. Mahner, S. Kahlert, N. Harbeck, A. Lebeau, W. Brenner, M. Schwaiger, et al. Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F]Fluorodeoxyglucose J. Clin. Oncol., February 1, 2009; 27(4): 535 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ben-Haim and P. Ell 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response J. Nucl. Med., January 1, 2009; 50(1): 88 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Nahmias and L. M. Wahl Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors J. Nucl. Med., November 1, 2008; 49(11): 1804 - 1808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Tateishi, C. Gamez, S. Dawood, H. W. D. Yeung, M. Cristofanilli, and H. A. Macapinlac Bone Metastases in Patients with Metastatic Breast Cancer: Morphologic and Metabolic Monitoring of Response to Systemic Therapy with Integrated PET/CT Radiology, April 1, 2008; 247(1): 189 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Hodgson and K. Y. Gulenchyn Is There a Role for Positron Emission Tomography in Breast Cancer Staging? J. Clin. Oncol., February 10, 2008; 26(5): 712 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens Application of PET/CT in the Development of Novel Anticancer Drugs Oncologist, January 1, 2008; 13(1): 25 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Kesner, W.-A. Hsueh, N. L. Htet, B. S. Pio, J. Czernin, M. D. Pegram, M. E. Phelps, and D. H.S. Silverman Biodistribution and Predictive Value of 18F-Fluorocyclophosphamide in Mice Bearing Human Breast Cancer Xenografts J. Nucl. Med., December 1, 2007; 48(12): 2021 - 2027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Rosen, W. B. Eubank, and D. A. Mankoff FDG PET, PET/CT, and Breast Cancer Imaging RadioGraphics, October 1, 2007; 27(suppl_1): S215 - S229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Francis, M. J. Byrne, A. A. van der Schaaf, J. A. Boucek, A. K. Nowak, M. Phillips, R. Price, A. P. Patrikeos, A. W. Musk, and M. J. Millward Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans J. Nucl. Med., September 1, 2007; 48(9): 1449 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-M. S. Kong, K. A. Frey, L. E. Quint, R. K. T. Haken, J. A. Hayman, M. Kessler, I. J. Chetty, D. Normolle, A. Eisbruch, and T. S. Lawrence A Pilot Study of [18F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Non Small-Cell Lung Cancer J. Clin. Oncol., July 20, 2007; 25(21): 3116 - 3123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Ehman, W. R. Hendee, M. J. Welch, N. R. Dunnick, L. B. Bresolin, R. L. Arenson, S. Baum, H. Hricak, and J. H. Thrall Blueprint for Imaging in Biomedical Research Radiology, July 1, 2007; 244(1): 12 - 27. [Full Text] [PDF]
|
|
|
|
|
|
C. Nahmias, W. T. Hanna, L. M. Wahl, M. J. Long, K. F. Hubner, and D. W. Townsend Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients with 18F-FDG PET/CT J. Nucl. Med., May 1, 2007; 48(5): 744 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kuehl, P. Veit, S. J. Rosenbaum, A. Bockisch, and G. Antoch Can PET/CT Replace Separate Diagnostic CT for Cancer Imaging? Optimizing CT Protocols for Imaging Cancers of the Chest and Abdomen J. Nucl. Med., January 1, 2007; 48(1_suppl): 45S - 57S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-A. Hsueh, A. L. Kesner, A. Gangloff, M. D. Pegram, M. Beryt, J. Czernin, M. E. Phelps, and D. H.S. Silverman Predicting Chemotherapy Response to Paclitaxel with 18F-Fluoropaclitaxel and PET J. Nucl. Med., December 1, 2006; 47(12): 1995 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Couturier, G. Jerusalem, J.-M. N'Guyen, and R. Hustinx Sequential Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Response to Chemotherapy in Metastatic Breast Cancer. Clin. Cancer Res., November 1, 2006; 12(21): 6437 - 6443. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
